Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Change in Receivables (2019 - 2025)

Cue Biopharma (CUE) has disclosed Change in Receivables for 7 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 333.76% to $5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, up 711.02% year-over-year, with the annual reading at $4.6 million for FY2025, 711.02% up from the prior year.
  • Change in Receivables hit $5.2 million in Q4 2025 for Cue Biopharma, up from -$145000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $5.2 million in Q4 2025 to a low of -$2.2 million in Q1 2022.
  • Historically, Change in Receivables has averaged $206452.2 across 5 years, with a median of $49000.0 in 2022.
  • Biggest five-year swings in Change in Receivables: crashed 55350.0% in 2022 and later surged 776.67% in 2023.
  • Year by year, Change in Receivables stood at $2.4 million in 2021, then crashed by 131.13% to -$738000.0 in 2022, then skyrocketed by 105.15% to $38000.0 in 2023, then plummeted by 5907.89% to -$2.2 million in 2024, then soared by 333.76% to $5.2 million in 2025.
  • Business Quant data shows Change in Receivables for CUE at $5.2 million in Q4 2025, -$145000.0 in Q3 2025, and $532000.0 in Q2 2025.